HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT OF THE GENKYOTEX COMPANY CONTRACT WITH THE KEPLER CHEUVREUX COMPANY

<!–

–>

Regulatory News:

Under the liquidity contract entrusted by the company Genkyotex (Paris: GKTX) (Brussels: GKTX) to Kepler Cheuvreux with effect from May 7, 2018, the following resources appeared in the liquidity account on December 31, 2020:

  • 9 243 actions Genkyotex;

  • € 13,467.52 in cash

Over the period from 07/01/2020 to 12/31/2020, were carried out:

– 147 purchase transactions

– 127 transactions for sale

Over this same period, the volumes traded represented:

– 18,814 shares and 47,956.14 euros on purchase

– 21,036 shares and 54,129.05 euros for sale

It is recalled that under the liquidity contract the following resources were included in the liquidity account during the half-year report on June 30, 2020:

  • 11 465 actions Genkyotex;

  • € 7,330.03 in cash.

Over the period from 1/1/2020 to 30/6/2020, were carried out:

– 262 purchase transactions

– 185 transactions for sale

Over this same period, the volumes traded represented:

– 71,504 securities shares and 154,179.10 euros for purchase

– 67,828 securities shares and 147,094.25 euros for sale

About Genkyotex

Genkyotex is a leading biopharmaceutical company in NOX therapies, listed on the regulated markets of Euronext Paris and Euronext Brussels. Its unique therapeutic approach is based on the selective inhibition of NOX enzymes which amplify many pathological processes such as fibrosis, inflammation, pain perception, cancer progression and neurodegeneration. Genkyotex is developing a portfolio of drug candidates representing a new therapeutic class targeting one or more NOX enzymes. Its most advanced drug candidate, setanaxib (GKT831), an inhibitor of NOX1 and 4 enzymes, demonstrates anti-fibrotic activity in a Phase 2 clinical trial in primary biliary cholangitis (PBC, an orphan fibrotic disease). Following the positive results, a Phase 3 clinical trial in CBP is planned. Setanaxib is also being evaluated in a clinical trial initiated by investigators in type 1 diabetes and diabetic nephropathy (DKD). An $ 8.9M grant from the US National Institutes of Health (NIH) was awarded to Professor Victor Thannickal of the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that leads to fibrosis of the lungs. The central element of the program is the conduct of a Phase 2 trial with setanaxib in patients with IPF whose first patient was recruited in September 2020. This candidate could also be active in other fibrotic indications.

Genkyotex also has a versatile platform, Vaxiclase, which is particularly suitable for the development of immunotherapies. A partnership on the use of Vaxiclase as an antigen itself (GTL003) has been established with the Serum Institute of India Private Ltd (Serum Institute), the world’s largest producer of vaccine doses, for development by the Serum Institute of multivalent cell combination vaccines against several infectious diseases.

More information on the website www.genkyotex.com or on investors@genkyotex.com

Cautionary Note

This announcement does not constitute an invitation to participate in the current tender offer for the shares of Genkyotex or to offer the shares of Genkyotex in or from any jurisdiction in which, to or from any person, it is illegal to make such an invitation under applicable securities laws. The distribution of this announcement in certain jurisdictions may be restricted by law. Persons in possession of this announcement are required to inform themselves about these restrictions and to comply with them.

This press release may contain information of a forward-looking nature concerning the Company’s objectives. These forward-looking statements are based on the assumptions, estimates and expectations of Genkyotex management and are subject to certain risks and uncertainties such as the ability of the company to implement its strategy, market trends, changes in technologies and the competitive environment, regulatory changes, industrial and clinical risks as well as all the risks associated with the development of the company. These factors, along with other risks and uncertainties, may prevent the company from achieving the objectives mentioned in this press release and, consequently, actual results may differ from what is stated therein. Factors that could influence future results also include, without being exhaustive, uncertainties related to the development of Genkyotex’s products that may not be successful, uncertainties related to product marketing authorizations given by the competent administrative authorities, as well as any factor which could influence Genkyotex’s ability to market the products it develops. No guarantee can be given as to the realization of these forward-looking statements which are subject to risks such as, in particular, described in the universal registration document of Genkyotex filed with the Autorité des marchés financiers on April 30, 2020 under the number D. 20-0434, and to changes in economic conditions, financial markets or the markets in which Genkyotex is present. Genkyotex products are currently used exclusively in clinical trials. They are not available outside of these trials or for sale.

Purchases

Sales

Name of

transactions

Name of

securities

Capital in EUR

Name of

transactions

Name of

securities

Capital in EUR

Total

147

18 814

47 956,14

127

21 036

54 129,05

01/07/2020

6

501

1 102,20

1

1

2,26

02/07/2020

3

500

1 100,00

03/07/2020

3

115

253,00

5

501

1 122,24

06/07/2020

3

186

409,20

07/07/2020

1

1

2,20

5

2 108

4 785,16

09/07/2020

2

301

668,22

6

1 001

2 252,25

10/07/2020

1

1

2,27

1

1

2,27

13/07/2020

3

601

1 346,24

1

1

2,25

14/07/2020

4

301

668,22

1

1

2,23

15/07/2020

1

300

660,00

2

700

1 589,00

16/07/2020

1

1

2,21

1

1

2,21

17/07/2020

1

1

2,24

6

501

1 132,26

20/07/2020

6

1 266

2 949,78

12

3 092

7 358,96

21/07/2020

18

1 934

4 390,18

10

1 400

3 248,00

22/07/2020

6

601

1 358,26

2

2

4,72

23/07/2020

1

200

452,00

4

400

916,00

24/07/2020

3

405

903,15

1

200

452,00

27/07/2020

6

1 095

2 419,95

5

600

1 344,00

28/07/2020

3

401

882,20

4

401

894,23

29/07/2020

7

901

1 946,16

5

376

823,44

30/07/2020

3

501

1 052,10

1

1

2,15

31/07/2020

1

1

2,14

04/08/2020

1

91

189,28

4

724

1 563,84

05/08/2020

3

22

47,08

2

201

442,20

06/08/2020

2

21

44,94

4

401

886,21

07/08/2020

3

392

834,96

1

1

2,20

10/08/2020

4

756

1 632,96

12/08/2020

1

1

2,20

2

2

4,40

14/08/2020

2

500

1 440,00

20/08/2020

1

1

2,93

1

1

2,93

21/08/2020

2

501

1 452,90

1

1

2,91

25/08/2020

1

1

2,94

1

1

2,94

26/08/2020

1

1

2,91

1

1

2,91

28/08/2020

1

21

62,16

01/09/2020

1

479

1 417,84

03/09/2020

1

1

2,96

1

1

2,96

08/09/2020

1

500

1 500,00

09/09/2020

1

1 000

3 100,00

10/09/2020

2

1 000

3 040,00

11/09/2020

3

161

492,66

1

1

3,08

14/09/2020

2

341

1 043,46

1

1

3,07

15/09/2020

1

1 000

3 100,00

17/09/2020

1

300

906,00

18/09/2020

2

117

352,17

4

1 000

3 060,00

21/09/2020

1

1 000

3 100,00

23/09/2020

1

1

3,05

5

1 001

3 083,08

25/09/2020

3

501

1 523,04

3

412

1 268,96

28/09/2020

2

384

1 155,84

1

1

3,05

29/09/2020

1

1

3,07

1

1

3,07

30/09/2020

1

1

3,05

1

1

3,05

01/10/2020

1

500

1 500,00

02/10/2020

1

1

3,03

1

1

3,03

05/10/2020

1

1

3,02

1

1

3,02

06/10/2020

7

501

1 523,04

1

1

3,05

08/10/2020

7

1 000

3 010,00

09/10/2020

3

500

1 500,00

12/10/2020

3

1 001

2 982,98

1

1

3,05

13/10/2020

2

200

600,00

15/10/2020

2

401

1 182,95

1

1

2,97

19/10/2020

3

1 000

3 000,00

22/10/2020

1

1

2,94

26/10/2020

1

490

1 455,30

Business Wire 2021

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.